ADMA Biologics (NASDAQ:ADMA) Stock Price Down 3.4% – Time to Sell?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price fell 3.4% on Friday . The stock traded as low as $21.01 and last traded at $21.08. 348,220 shares changed hands during trading, a decline of 90% from the average session volume of 3,606,443 shares. The stock had previously closed at $21.83.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ADMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Price Performance

The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average price is $19.08 and its two-hundred day moving average price is $15.23. The company has a market cap of $4.72 billion, a price-to-earnings ratio of 72.86 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the company earned $0.01 EPS. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 5.52 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co lifted its position in shares of ADMA Biologics by 114.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock valued at $357,000 after acquiring an additional 28,832 shares during the period. Lazard Asset Management LLC grew its stake in ADMA Biologics by 5.5% during the first quarter. Lazard Asset Management LLC now owns 110,809 shares of the biotechnology company’s stock worth $730,000 after buying an additional 5,731 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in ADMA Biologics by 13.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 60,924 shares of the biotechnology company’s stock valued at $403,000 after buying an additional 7,450 shares during the period. CWM LLC raised its position in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of ADMA Biologics by 3,084.6% during the 2nd quarter. SG Americas Securities LLC now owns 363,742 shares of the biotechnology company’s stock worth $4,067,000 after acquiring an additional 352,320 shares during the period. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.